Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide?

Abstract

A patient with secondary acute myelomonocytic leukemia after treatment with chronic oral etoposide (VP-16) for lung cancer is reported. The leukemic cells showed a t(9;11)(p22;q23) translocation. Southern blot analysis revealed the rearrangement of the MLL (ALL-1/HRX) gene at 11q23. Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed a chimeric mRNA between the MLL gene at 11q23 and LTG9 (MLLT3/AF-9) gene at 9p22. The patient was successfully treated with a VP-16 based regimen. This case is instructive in the understanding of the leukemogenesis of VP-16-related leukemias.

• Authors: H Goto, C Shimazaki, T Tatsumi, N Yamagata, T Inaba, N Fujita, T Moriguchi, K Yamamoto, M Seto, R Ueda
• Journal: International journal of hematology (Int J Hematol) Vol. 60 Issue 2 Pg. 145-9 (Aug 1994) ISSN: 0925-5710 [Print] Japan
• PMID: 7948964 (Publication Type: Case Reports, Journal Article)

Chemical References

• Etoposide

Topics

• Administration, Oral
• Aged
• Base Sequence
• Carcinoma, Small Cell (drug therapy)
• Chromosomes, Human, Pair 11
• Chromosomes, Human, Pair 9
• Drug Administration Schedule
• Etoposide (administration & dosage, adverse effects)
• Genes (drug effects)
• Humans
• Leukemia, Myelomonocytic, Acute (chemically induced, genetics)
• Lung Neoplasms (drug therapy)
• Male
• Molecular Sequence Data
• Neoplasms, Second Primary (chemically induced, genetics)
• Polymerase Chain Reaction
• Translocation, Genetic